Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase iv

Endocrinology

Volumn 136, Issue 8, 1995, Pages 3585-3596

  Kieffer, Timothy J ^a,b   Mc Intosh, Christopher H S ^a   Pederson, Raymond A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; HORMONAL REGULATION; INSULIN METABOLISM; INSULIN RELEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RAT;

ANIMAL; ANTIGENS, CD26; BLOOD PHYSIOLOGY; GLUCAGON; GLUCOSE; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN PRECURSORS; RATS; RATS, INBRED F344; RATS, WISTAR; SUPPORT, NON-U.S. GOV'T;

EID: 0029118049     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/endo.136.8.7628397     Document Type: Article

References (50)

1. Unger RH, Eisentraut AM 1969 Entero-insular axis. Arch Intern Med 123:261-266
2. Brown JC, Pederson RA, Jorpes E, Mutt V 1969 Preparation of highly active enterogastrone. Can J Physiol Pharmacol 47:114-133
3. Brown JC, Mutt V, Pederson RA 1970 Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol 209: 57-64
4. Bell GI, Santerre RF, Mullenbach GT 1983 Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302:716-718
5. Lopez LC, Frazier ML, Su CJ, Humar A, Sanders GF 1983 Mammalian pancreatic preproglucagon contains three glucagon-related peptides. Proc Natl Acad Sci USA 80:5485-5489
6. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF 1986 Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880-11889
7. Holst JJ, Orskov C 1994 Glucagon and other proglucagon-derived peptides. In: Walsh JH, Dockray GJ (eds) Gut Peptides: Comprehensive Endocrinology. Raven Press, New York, pp 305-340
8. Pederson RA 1994 Gastric inhibitory polypeptide. In: Walsh JH, Dockray GJ (eds) Gut Peptides: Comprehensive Endocrinology. Raven Press, New York, pp 217-260
9. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S 1992 Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326: 1316-1322
10. Holz GG, Kühtreiber WM, Habener JF 1993 Pancreatic β-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-l(7-37). Nature 361:362-365
11. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF 1992 Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276
12. Nauck MA, Heimesaat MM, Frskov C, Holst JJ, Ebert R, Creutzfeldt W 1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest 91:301-307
13. Brown JC, Dryburgh JR, Ross SA, Dupré J 1975 Identification and actions of gastric inhibitory polypeptide. Recent Prog Horm Res 31:487-532
14. Elahi D, Andersen DK, Brown JC, Debas HT, Hershcopf RJ, Raizes GS, Tobin JD, Andres R 1979 Pancreatic a- and §-cell responses to GIP infusion in normal man. Am J Physiol 237:E185-E 191
15. Sarson DL, Hayter RC, Bloom SR 1982 The pharmacokinetics of porcine glucose-dependent insulinotropic polypeptide (GIP) in man. Eur J Clin Invest 12:457-461
16. Nauck MA, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G, Creutzfeldt W 1989 Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab 69: 654-662
17. Kreymann B, Ghatei MA, Williams G, Bloom SR 1987 Glucagonlike peptide 1 7-36: a physiological incretin in man. Lancet 2:1300-1304
18. Schjoldager BTG, Mortensen PE, Christiansen J, Orskov C, Holst JJ 1989 GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 34:703-708
19. Orskov C, Wettergren A, Holst JJ 1993 Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661
20. O'Doriso TM, Sirinek KR, Mazzaferri EL, Cataland S 1977 Renal effects on serum gastric inhibitory polypeptide (GIP). Metabolism 26:651-656
21. Hanks JB, Andersen DK, Wise JE, Putnam WS, Meyers WC, Jones RS 1984 The hepatic extraction of gastric inhibitory polypeptide and insulin. Endocrinology 115:1011-1018
22. Chap Z, O'Dorisio TM, Cataland S, Field JB 1987 Absence of hepatic extraction of gastric inhibitory polypeptide in conscious dogs. Dig Dis Sci 32:280-284
23. Orskov C, Andreasen J, Holst JJ 1992 All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab 74:379-384
24. Ruiz-Grande C, Alarcón C, Alcántara A, Castilla C, López Novoa JM, Villanueva-Pertacarrillo ML, Valverde I1993 Renal catabolism of truncated glucagon-like peptide 1. Horm Metab Res 25:612-616
25. Mentlein R, Gallwitz B, Schmidt WE 1993 Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-l(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835
26. Tiruppathi C, Miyamoto Y, Ganapathy V, Roesel RA, Whitford G, Leibach FH 1990 Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains. J Biol Chem 265:1476-1483
27. Watanabe Y, Kojima T, Fujimoto Y 1987 Deficiency of membrane-bound dipeptidylaminopeptidase IV in a certain rat strain. Experi-entia 43:400-401
28. Thompson NL, Hixson DC, Callanan H, Panzica M, Flanagan D, Faris RA, Hong W, Hartel-Schenk S 1991 A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Biochem J 273:497-502
29. Erickson RH, Suzuki Y, Sedlmayer A, Kim YS 1992 Biosynthesis and degradation of altered immature forms of intestinal dipeptidyl peptidase IV in a rat strain lacking the enzyme. J Biol Chem 267: 21623-21629
30. Matumura C 1985 Dipeptidyl aminopeptidase IV (DAP IV) in urine. J Jpn Pediatr Soc 33:287-291
31. Morgan LM, Morris BA, Marks V 1978 Radioimmunoassay of gastric inhibitory polypeptide. Ann Clin Biochem 15:172-177
32. Verchere CB 1991 The Role of Gastric Inhibitory Polypeptide in the Regulation of Pancreatic Endocrine Secretion. PhD Thesis, University of British Columbia, Vancouver, Canada
33. Jomvall H, Carlquist M, Kwauk S, Otte SC, McIntosh CHS, Brown JC, Mutt V 1981 Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP). FEBS Lett 123:205-210
34. Brown JC, Dahl M, Kwauk S, McIntosh CHS, Muller M, Otte SC, Pederson RA 1981 Actions of GIP. Peptides [Suppl 2] 2:241-245
35. Buckley DI, Lundquist P 1992 Analysis of the degradation of in-sulinotropin [GLP-1-(7-37)] in human plasma and production of degradation resistant analogs. Regul Pept 40:117 (Abstract)
36. 2 terminus. J Clin Invest 78:906-913
37. Frohman LA, Downs TR, Heimer EP, Felix AM 1989 Dipepti-dylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 83: 1533-1540
38. Walter R, Simmons WH, Yoshimoto T 1980 Proline specific endo-and exopeptidases. Mol Cell Biochem 30:111-126
39. Martin RA, Cleary DL, Guido DM, Zurcher-Neely HA, Kubiak TM 1993 Dipeptidyl peptidase IV (DPP-IV) from pig kidney cleaves analogs of bovine growth hormone-releasing factor (bGRF) modified at position 2 with Ser, Thr, or Val. Extended DPP-IV substrate specificity? Biochim Biophys Acta 1164:252-260
40. Hopsu-Havu VK, Glenner GG 1966 A new dipeptide naphthyl-amidase hydrolyzing glycyl-prolyl-β-naphthylamide. Histochemie 7: 197-201
41. Yaron A, Naider F 1993 Proline-dependent structural and biological properties of peptides and proteins. Crit Rev Biochem Mol Biol 28:31-81
42. Ahmad S, Wang L, Ward PE 1992 Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. J Pharmacol Exp Ther 260:1257-1261
43. Schmidt WE, Siegel EG, Kümmel H, Gallwitz B, Creutzfeldt W 1987 Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39. Endocrinology 120:835-837
44. Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O 1994 Structure-activity studies of glucagon-like peptide-1. J Biol Chem 269:6275-6278
45. Gefel D, Hendrick GK, Mojsov S, Habener J, Weir GC 1990 Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3', 5'-monophosphate formation. Endocrinology 126:2164-2168
46. Grandt D, Sieburg B, Sievert J, Schimiczek M, Becker U, Holtmann G, Layer P, Reeve Jr JR, Eysselein VE, Goebell H, Müller M 1994 Is GLP-1 (9-36) amide an endogenous antagonist at GLP-1 receptors? Digestion 55:302 (Abstract)
47. Suzuki S, Kawai K, Ohashi S, Mukai H, Yamashita K 1989 Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. Endocrinology 125:3109-3114
48. Nagata T, Umeda Y, Urakami M, Inada M 1988 Urinary dipeptidyl aminopeptidase IV (DAP IV) activity in patients with impaired glucose tolerance and diabetes mellitus. J Jpn Diabetic Soc 31:169-171
49. Takasawa M, Kasahara S, Igarashi K 1990 Urinary glycylprolyl dipeptidylaminopeptidase acitivity in diabetes mellitus. J Jpn Diabetic Soc 33:287-291
50. Nukada O, Kobayashi M, Moriwake T, Kanzaki S, Himei H, Yoda T, Seino Y 1992 Urinary glycylprolyl dipeptidyl aminopeptidase (GP-DAP) in insulin-dependent diabetic patients. Acta Pediatr 81: 907-911